AAAAAA

   
Results: 1-16 |
Results: 16
Low prevalence of cardiac abnormalities in an HIV-seropositive population on antiretroviral combination therapy
Authors: Bijl, M Dieleman, JP Simoons, M van der Ende, ME
Citation: M. Bijl et al., Low prevalence of cardiac abnormalities in an HIV-seropositive population on antiretroviral combination therapy, J ACQ IMM D, 27(3), 2001, pp. 318-320
Papillary necrosis associated with the HIV protease inhibitor indinavir
Authors: Dieleman, JP van der Feltz, M Bangma, CH Stricker, BHC van der Ende, ME
Citation: Jp. Dieleman et al., Papillary necrosis associated with the HIV protease inhibitor indinavir, INFECTION, 29(4), 2001, pp. 232-233
Limited patient adherence to highly active antiretroviral therapy for HIV-1 infection in an observational cohort study
Authors: Nieuwkerk, PT Sprangers, MAG Burger, DM Hoetelmans, RMW Hugen, PWH Danner, SA van der Ende, ME Schneider, MME Schrey, G Meenhorst, PL Sprenger, HG Kauffmann, RH Jambroes, M Chesney, MA de Wolf, F Lange, JMA
Citation: Pt. Nieuwkerk et al., Limited patient adherence to highly active antiretroviral therapy for HIV-1 infection in an observational cohort study, ARCH IN MED, 161(16), 2001, pp. 1962-1968
Antiviral resistance of biologic HIV-2 clones obtained from individuals onnucleoside reverse transcriptase inhibitor therapy
Authors: van der Ende, ME Guillon, C Boers, PHM Ly, TD Gruters, RA Osterhaus, ADME Schutten, M
Citation: Me. Van Der Ende et al., Antiviral resistance of biologic HIV-2 clones obtained from individuals onnucleoside reverse transcriptase inhibitor therapy, J ACQ IMM D, 25(1), 2000, pp. 11-18
AVANTI 2. Randomized, double-blind trial to evaluate the efficacy and safety of zidovudine plus lamivudine versus zidovudine plus lamivudine plus indinavir in HIV-infected antiretroviral-naive patients
Authors: Gartland, M Gerstoft, J Goebel, F Clumeck, N Cooper, DA Gatell, J Gazzard, B Gerstoft, J Goebel, F Lange, J Montaner, J Reiss, P Rozenbaum, W Vella, S Beveridge, A Cooper, DA Duncombe, C Gold, J Haberl, M Clumeck, N Luyts, D Montaner, J Rachlis, A Marina, R Gerstoft, J Wandall, JH Elbrond, B Molina, JM Pialloux, G Rozenbaum, W Beauvais, L Goebel, FD Staszewski, S Bruns, I Hug, M Reiss, P Lange, J Frissen, PHJ van der Ende, ME Bosboom, M Baas, C Milazzo, F Moroni, M Panebianco, R Clotet, B Artigas, JMG Gonzalez-Lahoz, J Leal, M Rodriguez-Lopo, C Gandarias, B Gazzard, B Johnson, M McKinley, S Page, V Watkins, K Sandstrom, E Belsey, E Darbyshire, J Chodakewitz, J Isaacs, R Jonas, L Meibohm, A Coughlan, M Fiddian, P Gartland, M Harrigan, R Larder, B Maguire, M Millard, J Moore, S Patel, K Shortino, D Tisdale, M Vafidis, I Yeo, J
Citation: M. Gartland et al., AVANTI 2. Randomized, double-blind trial to evaluate the efficacy and safety of zidovudine plus lamivudine versus zidovudine plus lamivudine plus indinavir in HIV-infected antiretroviral-naive patients, AIDS, 14(4), 2000, pp. 367-374
The effect of treatment intensification in HIV-infection: a study comparing treatment with ritonavir/saquinavir and ritonavir/saquinavir/stavudine
Authors: Gisolf, EH Jurriaans, S Pelgrom, J van Wanzeele, F van der Ende, ME Brinkman, K Borst, MJ de Wolf, F Japour, AJ Danner, SA
Citation: Eh. Gisolf et al., The effect of treatment intensification in HIV-infection: a study comparing treatment with ritonavir/saquinavir and ritonavir/saquinavir/stavudine, AIDS, 14(4), 2000, pp. 405-413
Once-daily indinavir plus ritonavir: preliminary results of the PIPO study
Authors: Burger, DM Hugen, PWH van der Ende, ME van Wijngaarden, P Aarnoutse, RE Reiss, P Lange, JMA
Citation: Dm. Burger et al., Once-daily indinavir plus ritonavir: preliminary results of the PIPO study, AIDS, 14(16), 2000, pp. 2621-2623
Cerebrospinal fluid HIV-1 RNA during treatment with ritonavir/saquinavir or ritonavir/saquinavir/stavudine
Authors: Gisolf, EH Enting, RH Jurriaans, S de Wolf, F van der Ende, ME Hoetelmans, RMW Portegies, P Danner, SA
Citation: Eh. Gisolf et al., Cerebrospinal fluid HIV-1 RNA during treatment with ritonavir/saquinavir or ritonavir/saquinavir/stavudine, AIDS, 14(11), 2000, pp. 1583-1589
Development of a real-time quantitative RT-PCR for the detection of HIV-2 RNA in plasma
Authors: Schutten, M van den Hoogen, B van der Ende, ME Gruters, RA Osterhaus, ADME Niesters, HGM
Citation: M. Schutten et al., Development of a real-time quantitative RT-PCR for the detection of HIV-2 RNA in plasma, J VIROL MET, 88(1), 2000, pp. 81-87
Broadening of coreceptor usage by human immunodeficiency virus type 2 doesnot correlate with increased pathogenicity in an in vivo model
Authors: van der Ende, ME Guillon, C Beers, PHM Gruters, RA Racz, P Tenner-Racz, K Osterhaus, ADME Schutten, M
Citation: Me. Van Der Ende et al., Broadening of coreceptor usage by human immunodeficiency virus type 2 doesnot correlate with increased pathogenicity in an in vivo model, J GEN VIROL, 81, 2000, pp. 507-513
CD4 T cells remain the major source of HIV-1 during end stage disease
Authors: van der Ende, ME Schutten, M Raschdorff, B Grossschupff, G Racz, P Osterhaus, ADME Tenner-Racz, K
Citation: Me. Van Der Ende et al., CD4 T cells remain the major source of HIV-1 during end stage disease, AIDS, 13(9), 1999, pp. 1015-1019
Urological complaints in relation to indinavir plasma concentrations in HIV-infected patients
Authors: Dieleman, JP Gyssens, IC van der Ende, ME de Marie, S Burger, DM
Citation: Jp. Dieleman et al., Urological complaints in relation to indinavir plasma concentrations in HIV-infected patients, AIDS, 13(4), 1999, pp. 473-478
Immune restoration does not invariably occur following long-term HIV-1 suppression during antiretroviral therapy
Authors: Pakker, NG Kroon, EDMB Roos, MTL Otto, SA Hall, D Wit, FWNM Hamann, D van der Ende, ME Claessen, FAP Kauffmann, RH Koopmans, PP Kroon, FP ten Napel, CHH Sprenger, HG Weigel, HM Montaner, JSG Lange, JMA Reiss, P Schellekens, PTA Miedema, F
Citation: Ng. Pakker et al., Immune restoration does not invariably occur following long-term HIV-1 suppression during antiretroviral therapy, AIDS, 13(2), 1999, pp. 203-212
A phase II safety and efficacy study of amprenavir in combination with zidovudine and lamivudine in HIV-infected patients with limited antiretroviralexperience
Authors: Haubrich, R Thompson, M Schooley, R Lang, W Stein, A Sereni, D van der Ende, ME Antunes, F Richman, D Pagano, G Kahl, L Fetter, A Brown, DJ Clumeck, N
Citation: R. Haubrich et al., A phase II safety and efficacy study of amprenavir in combination with zidovudine and lamivudine in HIV-infected patients with limited antiretroviralexperience, AIDS, 13(17), 1999, pp. 2411-2420
Substituting nevirapine for protease inhibitors because of intolerance
Authors: Dieleman, JP Gyssens, IC Sturkenboom, MJCM Niesters, HGM van der Ende, ME
Citation: Jp. Dieleman et al., Substituting nevirapine for protease inhibitors because of intolerance, AIDS, 13(11), 1999, pp. 1423-1424
Cyclosporine and triple-drug treatment with human immunodeficiency virus protease inhibitors
Authors: Gregoor, PJHS van Gelder, T van der Ende, ME Ijzermans, JNM Weimar, W
Citation: Pjhs. Gregoor et al., Cyclosporine and triple-drug treatment with human immunodeficiency virus protease inhibitors, TRANSPLANT, 68(8), 1999, pp. 1210-1210
Risultati: 1-16 |